X4 Pharmaceuticals, IncXFOREarnings & Financial Report
X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-25.8M
Net Profit
$-55.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.33
X4 Pharmaceuticals, Inc Q2 FY2023 Financial Summary
X4 Pharmaceuticals, Inc reported revenue of $0 for Q2 FY2023, with a net profit of $-55.7M (down 162.6% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-55.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2023 |
X4 Pharmaceuticals, Inc Quarterly Revenue & Net Profit History
X4 Pharmaceuticals, Inc results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $28.8M | — | $282.0K | 1.0% |
| Q1 FY2024 | $0 | — | $-51.8M | N/A |
| Q3 FY2023 | $0 | — | $-2.3M | N/A |
| Q2 FY2023 | $0 | — | $-55.7M | N/A |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q1 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $28.8M |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q1 2025 | |
|---|---|---|---|---|
| Assets | $173.4M | $173.3M | $112.2M | $130.0M |
| Liabilities | $105.9M | $105.7M | $111.1M | $107.1M |
| Equity | $67.5M | $67.6M | $1.0M | $22.9M |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q1 2025 | |
|---|---|---|---|---|
| Operating CF | $-47.9M | $-68.8M | $-33.6M | $-12.4M |